CL2016002386A1 - Formulaciones de factor ix liofilizadas. - Google Patents

Formulaciones de factor ix liofilizadas.

Info

Publication number
CL2016002386A1
CL2016002386A1 CL2016002386A CL2016002386A CL2016002386A1 CL 2016002386 A1 CL2016002386 A1 CL 2016002386A1 CL 2016002386 A CL2016002386 A CL 2016002386A CL 2016002386 A CL2016002386 A CL 2016002386A CL 2016002386 A1 CL2016002386 A1 CL 2016002386A1
Authority
CL
Chile
Prior art keywords
fix
formulations
liofilized
polipeptide
agent
Prior art date
Application number
CL2016002386A
Other languages
English (en)
Spanish (es)
Inventor
Brian M Thome
Cherie Parkhurst-Lang
Brandon W Leveille
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54196282&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002386(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of CL2016002386A1 publication Critical patent/CL2016002386A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mechanical Engineering (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Monitoring And Testing Of Transmission In General (AREA)
  • Mobile Radio Communication Systems (AREA)
CL2016002386A 2014-03-24 2016-09-22 Formulaciones de factor ix liofilizadas. CL2016002386A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461969801P 2014-03-24 2014-03-24

Publications (1)

Publication Number Publication Date
CL2016002386A1 true CL2016002386A1 (es) 2017-06-23

Family

ID=54196282

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002386A CL2016002386A1 (es) 2014-03-24 2016-09-22 Formulaciones de factor ix liofilizadas.

Country Status (16)

Country Link
US (3) US10772942B2 (enExample)
EP (1) EP3123090A4 (enExample)
JP (4) JP7058940B2 (enExample)
KR (1) KR102385372B1 (enExample)
AR (1) AR099838A1 (enExample)
AU (3) AU2015236340B2 (enExample)
CA (1) CA2943034C (enExample)
CL (1) CL2016002386A1 (enExample)
EA (2) EA038573B1 (enExample)
IL (3) IL247869B (enExample)
MA (1) MA39779A (enExample)
MX (2) MX387269B (enExample)
PH (1) PH12016501877A1 (enExample)
SG (3) SG11201607642RA (enExample)
TW (1) TWI700101B (enExample)
WO (1) WO2015148444A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI788044B (zh) 2013-03-15 2022-12-21 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
US10772942B2 (en) 2014-03-24 2020-09-15 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
IL319473A (en) * 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
BR112020000592A2 (pt) * 2017-07-11 2020-07-14 Universal Stabilization Technologies, Inc. método para conservar materiais biológicos
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
WO2021158759A2 (en) 2020-02-04 2021-08-12 Regeneron Pharmaceuticals, Inc. Target residual moisture content for lyophilized drug product
BR112022022869A2 (pt) * 2020-05-11 2023-01-31 Alkermes Pharma Ireland Ltd Composições de polipeptídeo de fusão de il-2 e métodos de fabricação e uso destas
CN118557531B (zh) * 2024-08-02 2024-10-18 成都蓉生药业有限责任公司 一种重组人凝血因子VIII-Fc融合蛋白冻干制剂的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
AU648020B2 (en) 1989-02-21 1994-04-14 Washington University Modified forms of reproductive hormones
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
MX9306133A (es) * 1992-10-02 1994-04-29 Kabi Pharmacia Ab Composicion que comprende una formulacion del factor de coagulacion viii, proceso para su preparacion y uso de un surfactante como estabilizador.
DE4405426A1 (de) 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
IN184589B (enExample) * 1996-10-16 2000-09-09 Alza Corp
US20010031721A1 (en) 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
AU7313400A (en) * 1999-09-17 2001-04-24 Takeda Chemical Industries Ltd. Process for producing protein powder
JP2001151694A (ja) 1999-09-17 2001-06-05 Takeda Chem Ind Ltd タンパク質粉体の製造法
MXPA02007733A (es) 2000-02-11 2004-09-10 Merck Patent Gmbh Mejoramiento de la vida media circulante de proteinas de fusion basadas en anticuerpos.
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
PL369065A1 (en) 2001-09-04 2005-04-18 Merck Patent Gmbh Modified factor ix
EP2277888A3 (en) 2001-12-21 2011-04-27 Human Genome Sciences, Inc. Fusion proteins of albumin and erythropoietin
EP3002012A1 (en) 2003-05-06 2016-04-06 Biogen Hemophilia Inc. Clotting factor-fc chimeric proteins to treat hemophilia
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
JP2005060378A (ja) 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd 生理活性蛋白質含有凍結乾燥製剤
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
ATE507822T1 (de) 2003-12-19 2011-05-15 Novo Nordisk Healthcare Ag Stabilisierte zusammensetzungen von faktor-vii- polypeptiden
BRPI0509117A (pt) 2004-03-04 2007-08-28 Wyeth Corp método de liofilização para melhorar a cristalização de excipientes
WO2006029467A1 (en) * 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
PT2371856T (pt) 2004-11-12 2022-08-12 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
NZ555503A (en) 2004-12-15 2010-01-29 Biovitrum Ab Publ Therapeutic formulations of keratinocyte growth factor
AU2006272804B2 (en) * 2005-07-22 2011-02-24 Amgen Inc. Concentrated protein lyophilates, methods, and uses
EP1951757B1 (en) * 2005-10-06 2014-05-14 Xencor, Inc. Optimized anti-cd30 antibodies
PT3225233T (pt) * 2005-11-01 2019-10-24 Wyeth Llc Solução de cloreto de sódio para reconstituição de fármacos.
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
PL2650305T3 (pl) 2006-03-24 2024-09-16 Bioverativ Therapeutics Inc. PC5 jako enzym przetwarzający propeptyd czynnika IX
US20090246187A1 (en) 2006-04-04 2009-10-01 Shire Pharmaceuticals Ireland Limited Process for concentration of a polypeptide
TW200804416A (en) 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
US8015841B2 (en) * 2006-09-08 2011-09-13 Praxair Technology, Inc. Cryogenic refrigeration system for lyophilization
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
CN101970678B (zh) 2007-06-21 2014-08-20 慕尼黑科技大学 具有增加的体内和/或体外稳定性的生物学活性蛋白
AU2008311973B2 (en) 2007-10-15 2013-10-03 Cangene Corporation Human Factor IX variants with an extended half life
BRPI0821591A2 (pt) 2007-12-21 2016-05-03 Inspiration Biopharmaceuticals Inc composição liofilizada e métodos de preparação de composição seca estável do fator ix e de liofilização de formulação farmacêutica
NZ603997A (en) 2007-12-27 2013-02-22 Baxter Int Chemically Modified Factor IX
JP2011517950A (ja) 2008-04-16 2011-06-23 バイエル・ヘルスケア・エルエルシー 第ｉｘ因子の部位特異的修飾
EP2288622A4 (en) 2008-04-16 2012-04-18 Bayer Healthcare Llc FACTOR IX MODIFIED POLYPEPTIDES AND USES THEREOF
EP2444491B1 (en) 2008-04-21 2016-11-16 Novo Nordisk Healthcare Ag Hyperglycosylated human coagulation factor IX
CA2722169A1 (en) 2008-04-24 2009-10-29 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
CA2729972C (en) 2008-08-05 2018-11-20 Wyeth Llc Lyophilization above collapse
CA2737407A1 (en) 2008-09-24 2010-04-01 Stabilitech Ltd. Method for preserving polypeptides using a sugar and polyethyleneimine
MX2011013722A (es) 2009-06-18 2012-05-08 Wyeth Llc Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
EP2458990B1 (en) 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
CN103140237A (zh) * 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 因子ix多肽及其使用方法
TWI507397B (zh) 2010-09-30 2015-11-11 Toyama Chemical Co Ltd ６－氟－３－羥－２－吡羧醯胺之美洛明鹽
EA029972B1 (ru) 2011-02-09 2018-06-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Способы получения полипептидных композиций
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
EP3542861A1 (en) * 2012-09-25 2019-09-25 Bioverativ Therapeutics Inc. Methods of using fix polypeptides
TWI788044B (zh) 2013-03-15 2022-12-21 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
US10772942B2 (en) 2014-03-24 2020-09-15 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations

Also Published As

Publication number Publication date
IL272257A (en) 2020-02-27
EA038573B1 (ru) 2021-09-16
NZ724351A (en) 2023-10-27
JP7503583B2 (ja) 2024-06-20
US20210069307A1 (en) 2021-03-11
JP7058940B2 (ja) 2022-04-25
WO2015148444A1 (en) 2015-10-01
MX2016012447A (es) 2017-01-06
IL272257B (en) 2021-03-25
TW201605492A (zh) 2016-02-16
SG10201808249VA (en) 2018-10-30
AU2020202863A1 (en) 2020-05-21
MX2021012939A (es) 2021-11-25
JP7759978B2 (ja) 2025-10-24
EP3123090A1 (en) 2017-02-01
US20170173122A1 (en) 2017-06-22
AR099838A1 (es) 2016-08-24
CA2943034C (en) 2022-06-14
IL247869B (en) 2020-02-27
JP2020063313A (ja) 2020-04-23
US10772942B2 (en) 2020-09-15
AU2022215218A1 (en) 2022-09-01
EA202092926A3 (ru) 2021-10-29
KR102385372B1 (ko) 2022-04-11
AU2022215218B2 (en) 2025-12-18
US12128092B2 (en) 2024-10-29
EP3123090A4 (en) 2017-12-13
AU2020202863B2 (en) 2022-09-01
SG10201913735SA (en) 2020-03-30
JP2022044689A (ja) 2022-03-17
JP2024053015A (ja) 2024-04-12
JP2017510585A (ja) 2017-04-13
MX387269B (es) 2025-03-18
PH12016501877A1 (en) 2016-12-19
KR20160137577A (ko) 2016-11-30
CA2943034A1 (en) 2015-10-01
EA201691807A1 (ru) 2017-03-31
IL281197A (en) 2021-04-29
MA39779A (fr) 2017-02-01
EA202092926A2 (ru) 2021-07-30
BR112016021777A2 (pt) 2017-10-03
IL247869A0 (en) 2016-11-30
IL281197B (en) 2022-06-01
TWI700101B (zh) 2020-08-01
AU2015236340B2 (en) 2020-02-06
SG11201607642RA (en) 2016-10-28
US20250121042A1 (en) 2025-04-17
AU2015236340A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
CL2016002386A1 (es) Formulaciones de factor ix liofilizadas.
BR112015003093A8 (pt) composições melhoradas de partículas substancialmente esféricas
EA201790248A1 (ru) Композиции носитель-антитело и способы их получения и применения
MX386615B (es) Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis.
BR112018012145A2 (pt) partículas de entrega de pró-sabor
BR112017011215A2 (pt) partículas de distribuição de pró-flavorizante
MX2017006268A (es) Administracion intranasal.
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
EA201892595A1 (ru) Назальные фармацевтические композиции с пористым наполнителем
MX2018014399A (es) Particulas de nanoalumbre que contienen un agente de dimensionamiento.
CL2017001605A1 (es) Composición farmacéutica que comprende plasminógeno y usos de este.
CR20190387A (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
MX2019010852A (es) Nanoparticulas a base de lipidos con estabilidad mejorada.
EA201600093A1 (ru) Дигидроксифенильные нейромедиаторные соединения, композиции и способы
PH12016501256A1 (en) Injectable agent and depot formation method
MX2016001619A (es) Formulaciones que contienen moduladores de gamma secretasa.
AU2016356504A8 (en) 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений
PH12018502139A1 (en) Phosphaplatin liquid formulations
MX2020002793A (es) Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados.
MX391331B (es) Composiciones de microesferas de gas encapsuladas en lipidos y metodos relacionados.
MX2017008714A (es) Composiciones lacteas espumantes.
MX2019006354A (es) Composicion de microparticulas derivadas de globulos rojos (rmp) y metodos de uso.
SG10201903357VA (en) Lipid encapsulated gas microsphere compositions and related methods